DrugPatentWatch Database Preview
Drugs in Development Information for Serlopitant
» See Plans and Pricing
What is the development status for investigational drug Serlopitant?
Serlopitant is an investigational drug.
There have been 12 clinical trials for Serlopitant.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 29th 2018.
The most common disease conditions in clinical trials are Pruritus, Prurigo, and Neurodermatitis. The leading clinical trial sponsors are Menlo Therapeutics Inc., Epidermolysis Bullosa Research Partnership, and Stanford University.
There are sixteen US patents protecting this investigational drug and seventy international patents.
Summary for Serlopitant
| US Patents | 16 |
| International Patents | 70 |
| US Patent Applications | 23 |
| WIPO Patent Applications | 55 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2018-08-29) |
| Vendors | 13 |
Recent Clinical Trials for Serlopitant
| Title | Sponsor | Phase |
|---|---|---|
| A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa | Epidermolysis Bullosa Research Partnership | Phase 2 |
| A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa | Menlo Therapeutics | Phase 2 |
| A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa | Stanford University | Phase 2 |
Clinical Trial Summary for Serlopitant
Top disease conditions for Serlopitant
Top clinical trial sponsors for Serlopitant
US Patents for Serlopitant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Serlopitant | Start Trial | Start Trial | ||
| Serlopitant | Start Trial | Use of NK-1 receptor antagonist serlopitant in pruritus | Menlo Therapeutics Inc. (Redwood, CA) | Start Trial |
| Serlopitant | Start Trial | Hydroisoindoline tachykinin receptor antagonists | Merck & Co., Inc. (Rahway, NJ) | Start Trial |
| Serlopitant | Start Trial | Hydroisoindoline tachykinin receptor antagonists | Merck & Co., Inc. (Rahway, NJ) | Start Trial |
| Serlopitant | Start Trial | Process for making hydroisoindoline tachykinin receptor antagonists | Merck & Co, Inc. (Rahway, NJ) | Start Trial |
| Serlopitant | Start Trial | Hydroisoindoline tachykinin receptor antagonists | Merck Sharp & Dohme Corp. (Rahway, NJ) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Serlopitant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Serlopitant | Australia | AU2014302694 | 2033-06-24 | Start Trial |
| Serlopitant | Australia | AU2020200259 | 2033-06-24 | Start Trial |
| Serlopitant | Brazil | BR112015031724 | 2033-06-24 | Start Trial |
| Serlopitant | Canada | CA2915474 | 2033-06-24 | Start Trial |
| Serlopitant | China | CN105473138 | 2033-06-24 | Start Trial |
| Serlopitant | European Patent Office | EP3013336 | 2033-06-24 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
